6:19 PM
 | 
May 23, 2012
 |  BC Extra  |  Top Story

Panel recommends against Xarelto for ACS

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-4, with one abstention, against recommending approval of 2.5 mg twice-daily Xarelto rivaroxaban from Johnson & Johnson (NYSE:JNJ) to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS), non-ST-elevation myocardial infarction...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >